Thoracic Re-irradiation For Locoregionally Recurrent Non-small Cell Lung Cancer

  • End date
    Feb 1, 2025
  • participants needed
  • sponsor
    Sun Yat-sen University
Updated on 27 February 2022


This prospective phase II study is to assess the efficacy and safety of thoracic re-irradiation for locoregionally recurrent non-small cell lung cancer using hypofractionated technique.


This prospective phase II study is to assess the efficacy and safety of thoracic re-irradiation for locoregionally recurrent non-small cell lung cancer using hypofractionated technique.

  1. For peripherally located recurrent tumors, stereotactic body radiation therapy is used at 5000-6000 cGy in 10 fractions.
  2. For centrally located recurrent tumors, adaptive hypofractionated radiation is used: Patients are irradiated at 3000-4000cGy in 6-10 daily fractions in the first course. After a four-week interval, patients who have non-progressive disease and an adequate pulmonary function undergo adaptive re-planning, and are irradiated at 2400-3500cGy in 4~7 daily fractions as a boost. Concurrent chemotherapy consists of weekly docetaxel and nedaplatin.

Condition Loco-regionally Recurrent NSCLC After Thoracic Radiotherapy
Treatment Concurrent chemotherapy, thoracic irradiation
Clinical Study IdentifierNCT04275687
SponsorSun Yat-sen University
Last Modified on27 February 2022


Yes No Not Sure

Inclusion Criteria

loco-regionally recurrent NSCLC after thoracic radiotherapy (confirmed by pathology or continuous enhanced CT imaging)
chemotherapy, targeted or immunotherapy are allowed before enrollment
>=6 months from previous chest radiotherapy
presence of measurable disease according to RECIST criteria
ECOG performance score is 0-1
organ and bone marrow functions meet the following criteria
forced expiratory volume in 1 second (FEV1) 0.8L
percentage-predicted single-breath carbon monoxide diffusing capacity (DLCO %) > 60%
absolute neutrophil count 1.510^9/L
platelet 8010^9/L
hemoglobin 9.0g/dL
serum creatinine clearance was 50 mL/min calculated based on the Cockcroft-Gault formula
serum bilirubin 1.5 times normal upper limit (ULN)
AST and ALT2.5 times ULN

Exclusion Criteria

previous or concurrent with other malignant tumors, except for non-melanoma of the skin or carcinoma in situ of the cervix
loco-regional recurrence with distant metastasis
any other disease or condition contradicted to radiotherapy (e.g., active infection, within 6 months after myocardial infarction, symptomatic heart disease, including unstable angina, congestive heart failure or uncontrolled arrhythmia, immunosuppressive therapy)
women who are pregnant or breastfeeding, women who have not undergone a pregnancy test (within 14 days before first administration), and women who are pregnant
pregnancy, lactation, or fertility but no contraceptive measures
those with bleeding tendency
participate in other clinical trials within 30 days before enrollment
drug and other drug addiction, chronic alcoholism and AIDS patients
having uncontrollable seizures or loss of self-control due to psychosis
a history of severe allergies
participants considered unfit to participate in this study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note